Showing 3441-3450 of 4164 results for "".
- OptiKira Awarded Phase 2 SBIR Grant to Support Development of Retinitis Pigmentosa Treatmenthttps://modernod.com/news/optikira-awarded-phase-2-sbir-grant-to-support-development-of-retinitis-pigmentosa-treatment/2476622/OptiKira announced that it was awarded a phase 2 Small Business Innovation Research (SBIR) grant to support continued development of a therapy that has the potential to preserve vision in patients with retinitis pigmentosa (RP). The $1.6M grant will be used to advance one or more of OptiKira’s mo
- Second Sight to Accelerate Development of Orion Visual Cortical Prosthesis Systemhttps://modernod.com/news/second-sight-to-accelerate-development-of-orion-visual-cortical-prosthesis-system/2476589/Second Sight Medical Products announced its plan to accelerate the development and commercialization of its Orion Visual Cortical Prosthesis System. Orion holds the potential to provide useful artificial vision to individuals blind from many causes, including glaucoma, eye injury, diabetic retino
- Iridex’s MicroPulse Laser Technology Featured in Several Glaucoma and Retina Research Presentationshttps://modernod.com/news/iridexs-micropulse-laser-technology-featured-in-several-glaucoma-and-retina-research-presentations/2476514/Iridex announced that its patented MicroPulse technology played a pivotal role in research presented at the 2019 Association for Research in Vision & Ophthalmology (ARVO) and American Society of Cataract & Refractive Surgeons (ASCRS) meetings, to be held in Vancouver and San Diego, respec
- Implandata Gains CE Mark for its Eyemate System for Keratoprosthesishttps://modernod.com/news/implandata-gains-ce-mark-for-its-eyemate-system-for-keratoprosthesis/2476510/Ophthalmic sensors and digital health company Implandata Ophthalmic Products announced that it attained CE mark for its Eyemate system for use in patients undergoing keratoprosthesis surgery. Keratoprosthesis represents an infrequent yet important procedure for restoring vision. It is performed o
- Allergan to Showcase New Data at ARVOhttps://modernod.com/news/allergan-to-showcase-new-data-at-arvo/2476496/Allergan will present new data at the Annual Meeting of The Association for Research in Vision and Ophthalmology (ARVO) to be held in Vancouver, British Columbia from April 28 – May 2. Data will include three paper presentations on the company’s ophthalmology pipeline including
- Results of Lumega-Z Data to be Presented at ARVOhttps://modernod.com/news/results-of-lumega-z-data-to-be-presented-at-arvo/2476474/Guardion Health Sciences Scientific Advisory Board member William Sponsel, MD, will be presenting an abstract at the Association for Research in Vision and Ophthalmology (ARVO) 2019 Annual Meeting in Vancouver, Canada, which will be held from April 28, 2019 to May 2, 2019. The abstract is titled
- Alcon Launches Project Presbyopia to Educate Eye Care Providers and Consumers During Presbyopia Awareness Monthhttps://modernod.com/news/alcon-launches-project-presbyopia-to-educate-eye-care-providers-and-consumers-during-presbyopia-awareness-month/2476460/Alcon is launching Project Presbyopia as part of Presbyopia Awareness Month in April. Project Presbyopia is an ongoing effort to educate consumers about how to recognize signs and symptoms of vision changes, uncover more intuitive language for the condition, and drive existing and emerging presby
- STAAR Surgical Celebrates 1 Million Lens Milestone for Implantable Collamer Lenshttps://modernod.com/news/staar-surgical-celebrates-1-million-lens-milestone-for-implantable-collamer-lens/2476459/STAAR Surgical announced that more than 1 million Visian implantable collamer lenses (ICLs) have been implanted globally. Currently approved versions of the ICL available in more than 75 countries around the world address the explosive growth of myopia, the need for distance vision cor
- Stealth BioTherapeutics Doses First Patient in Phase 2 Study of Elamipretide for the Treatment of Dry AMDhttps://modernod.com/news/stealth-biotherapeutics-announces-dosing-of-first-patient-in-phase-2-study-of-elamipretide-for-the-treatment-of-dry-amd/2476423/Stealth BioTherapeutics announced that it has dosed the first patient in ReCLAIM-2, a phase 2 study of elamipretide in patients with dry age-related macular degeneration (AMD) with geographic atrophy. “People with dry AMD can ultimately lose central vision. However, long before that
- Topcon Unveils New Maestro Unlimited OCT System at VEE 2019https://modernod.com/news/topcon-to-present-new-solution-for-oct-and-data-management-at-vee-2019/2476407/Topcon showcased several innovative new offerings at the Vision Expo East (VEE) conference in New York City. Topcon unveiled the new Maestro Unlimited, which pairs the Maestro 3D OCT with the new Topcon Harmony, a web-based data management application that provides unlimited device connect